Pleine Vie on MSN
Cancer de la prostate : l’apalutamide réduit de 20 % le risque de métastases ou de décès après chirurgie
Près d’un homme sur deux opéré d’un cancer de la prostate à haut risque voit la maladie revenir. Un nouveau schéma avec ...
Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...
A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...
Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...
Credit: Getty Images Investigators explore the biomarker potential of circulating tumor DNA and tumor suppressor gene status. Elevated circulating tumor DNA fraction and tumor suppressor gene loss are ...
PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...
L'Erleada, le médicament contre le cancer de la prostate de Johnson & Johnson, administré avec une thérapie hormonale six mois avant et après une intervention chirurgicale, a amélioré les chances ...
A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...
Doctissimo on MSN
Cancer : les médicaments comme Ozempic et Mounjaro réduiraient le risque de métastases jusqu'à 50 %
Conçus à l’origine pour traiter le diabète puis l’obésité, les médicaments de la famille des GLP-1 pourraient-ils également ...
Les résultats de l’essai international PROTEUS, présentés à l’ASCO en mai 2026, marquent un tournant majeur dans le ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results